Changes in vascular function and correlation with cardiotoxicity in women with newly diagnosed breast cancer undergoing HER2-directed therapy with and without anthracycline/cyclophosphamide

The objective of this study was to assess the effect of HER2-directed therapy (HER2-Tx) on peripheral vasoreactivity and its correlation with cardiac function changes and the additive effects of anthracycline/cyclophosphamide (AC) therapy and baseline cardiovascular risk. Single-centre, prospective...

Full description

Saved in:
Bibliographic Details
Published in:European heart journal open 2024-01, Vol.4 (1), p.oead130-oead130
Main Authors: Hazim, Antonious, Nhola, Lara F, Kailash, Vidur, Zhang, Song, Sandhu, Nicole P, Lerman, Amir, Loprinzi, Charles L, Ruddy, Kathryn J, Villarraga, Hector R, Lewis, Bradley, Herrmann, Joerg
Format: Article
Language:English
Subjects:
Anthracyclines
Cardiovascular diseases
Complications and side effects
Cyclophosphamide
Development and progression
Dosage and administration
Drug therapy, Combination
Methods
Original
Risk factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The objective of this study was to assess the effect of HER2-directed therapy (HER2-Tx) on peripheral vasoreactivity and its correlation with cardiac function changes and the additive effects of anthracycline/cyclophosphamide (AC) therapy and baseline cardiovascular risk. Single-centre, prospective cohort study of women with newly diagnosed stage 1-3 HER2-positive breast cancer undergoing HER2-Tx +/- AC. All participants underwent baseline and 3-monthly evaluations with Endo-Peripheral Arterial Tonometry (Endo-PAT), vascular biomarkers [C-type natriuretic peptide (CNP) and neuregulin-1 beta (NRG-1β)], and echocardiography. Cardiotoxicity was defined as a decrease in the left ventricular ejection fraction (LVEF) of >10% to a value
ISSN:2752-4191
2752-4191
DOI:10.1093/ehjopen/oead130